 |
Talon Therapeutics' Product Candidate Marqibo(R) to be Assessed by Oncologic Drug Advisory Committee (ODAC) on March 21, 2012 With a PDUFA Date of May 13, 2012
Feb 3, 2012
|
68.3 KB |
|
| |
SAN MATEO, Calif., Feb. 3, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc. (OTCBB:TLON) announced Marqibo® (vincristine sulfate liposomes injection) is scheduled to be assessed by ODAC on Wednesday, March 21, 2012. Talon's New Drug Application (NDA) for Marqibo was accepted for filing by the FDA and is being reviewed under Subpart H — A...
|
|
Talon Therapeutics Announces $11M Financing
Jan 9, 2012
|
22.4 KB |
|
| |
SAN MATEO, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc., (OTCBB:TLON), today announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield Management, its largest shareholders, for the sale of $11 million in preferred stock. Talon intends to use the net proceeds from the financing to advance its cl...
|
|
Talon Therapeutics Announces First Patient Enrolled in the Phase 3 OPTIMAL>60 Study of Marqibo(R) in Adult Patients With Newly Diagnosed, Aggressive Non-Hodgkin's Lymphoma
Nov 29, 2011
|
23.2 KB |
|
| |
Conducted by the prestigious German High-Grade NHL Study Group
R-CHMP-14 (M=Marqibo) versus R-CHOP-14 (O=standard vincristine)
Powered to demonstrate superior progression-free survival of R-CHMP-14
SAN MATEO, Calif., Nov. 29, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced the enrollmen...
|
|
Talon Therapeutics, Inc. Reports Third Quarter 2011 Financial Results
Nov 14, 2011
|
36.1 KB |
|
| |
SAN MATEO, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and nine months ended September 30, 2011.
"In the third quarter of 2011, we achieved two significant accomplishments: the acceptance for filing of our NDA seeking accelerated approval of Marqibo® a...
|
|
Talon Therapeutics to Host a Conference Call to Report Third Quarter 2011 Financial Results and Business Update on November 15, 2011
Nov 11, 2011
|
22.6 KB |
|
| |
SAN MATEO, Calif., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Tuesday, November 15, 2011 at 9:00AM PT, to include a discussion of financial results and highlights of the third quarter and a business update.
Conference call details:
Date:
Tu...
|
|
Talon Therapeutics' New Drug Application for Marqibo(R) Accepted for Filing by the United States Food and Drug Administration
Sep 27, 2011
|
68.6 KB |
|
| |
Accelerated approval review path confirmed by the FDA
Prescription Drug User Fee Act (PDUFA) date set for May 13, 2012
SAN MATEO, Calif., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) announced its new drug application (NDA) seeking accelerated approval of Marqibo® (vincristine sulfate liposomes...
|
|
Talon Therapeutics Receives Special Protocol Assessment Agreement from the Food and Drug Administration for Its Phase 3 Confirmatory Study of Marqibo(R) in Newly Diagnosed Acute Lymphoblastic Leukemia
Aug 29, 2011
|
73.7 KB |
|
| |
SAN MATEO, Calif., Aug. 29, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), announced today the company has reached agreement with the U. S. Food and Drug Administration (FDA) regarding a special protocol assessment (SPA) for its planned Phase 3 study of Marqibo® (vincristine sulfate liposomes injection) in adults with newly d...
|
|
Talon Therapeutics, Inc. Reports Second Quarter 2011 Financial Results
Aug 15, 2011
|
35.3 KB |
|
| |
SAN MATEO, Calif., Aug. 15, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and six months ended June 30, 2011.
"Submitting our new drug application for Marqibo® was a momentous event for Talon. It was the culmination of exceptional dedication on the part of our employees ...
|
|
Talon Therapeutics to Host a Conference Call to Report Second Quarter 2011 Financial Results and Business Update on August 15, 2011
Aug 9, 2011
|
23.1 KB |
|
| |
SAN MATEO, Calif., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Monday, August 15, 2011 at 8:30AM PT, to include a discussion of results and highlights of the second quarter and a business update.
Conference call details:
Date:
Mond...
|
|
Talon Therapeutics Announces First Patient Enrolled in National Cancer Institute Phase 1 Trial of Marqibo(R) in Children and Adolescents
Jul 20, 2011
|
26.0 KB |
|
| |
SAN MATEO, Calif., July 20, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced the enrollment of the first patient in a Phase 1 trial to evaluate the safety, activity and pharmacokinetics of Marqibo® (vincristine sulfate liposomes injection) in children and adolescents with relapsed or refractory cancer being conduc...
|
|
Talon Therapeutics Submits New Drug Application for Marqibo(R)
Jul 18, 2011
|
70.7 KB |
|
| |
SAN MATEO, Calif., July 18, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced its New Drug Application (NDA) for Marqibo (vincristine sulfate liposomes injection) was submitted to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of Marqibo in adult Ph- ALL, in second or greater relapse or that ha...
|
|
Talon Therapeutics Provides NDA Submission Timeline Update for Marqibo(R)
Jun 30, 2011
|
25.2 KB |
|
| |
SAN MATEO, Calif., June 30, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today provided an update of the status of its planned NDA submission for Marqibo ((vincristine sulfate liposomes injection).
"I am pleased to announce that all of the Non-Clinical, Clinical and Quality (Chemistry, Manufacturing and Controls) modules o...
|
|
Talon Therapeutics Presents Marqibo(R) Hematopoietic Stem Cell Transplantation (HSCT) "Bridging" Data at American Society of Clinical Oncology 2011 Annual Meeting
Jun 6, 2011
|
26.9 KB |
|
| |
Marqibo enabled bridging to HSCT in 12 of 65 (18.5%) patients
There were 5 long-term survivors (greater than one year survival)
SAN MATEO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) presented a poster titled "VSLI (vincristine sulfate liposomes injection, Marqibo) "Bridging" to Potentially C...
|
|
Talon Therapeutics, Inc. Reports First Quarter 2011 Financial Results
May 13, 2011
|
33.3 KB |
|
| |
SAN MATEO, Calif., May 13, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON), today reported financial results for the first quarter ended March 31, 2011.
"Our primary focus for the first three months of 2011 was the preparation of our NDA filing for Marqibo®," stated Steven R. Deitcher, M.D., President, Chief Executive Of...
|
|
Talon Therapeutics to Commence a Phase 3 Study of Marqibo(R) in Adult Patients With Newly Diagnosed Non-Hodgkin's Lymphoma (NHL)
May 10, 2011
|
26.8 KB |
|
| |
Conducted by the prestigious German High-Grade NHL Study Group
R-CHMP (M=Marqibo) versus R-CHOP (O=standard vincristine)
Enrollment anticipated in third quarter 2011
SAN MATEO, Calif., May 10, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced the initiation of a Phase 3 Study of Marqibo (...
|
|
Talon Therapeutics to Host a Conference Call to Report First Quarter 2011 Financial Results and Business Update on May 13, 2011
May 9, 2011
|
22.2 KB |
|
| |
SAN MATEO, Calif., May 9, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Friday, May 13, 2011 at 8AM PT, to include a discussion of results and highlights of the first quarter and a business update.
Conference call details:
...
|
|
Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2010 Financial Results
Mar 28, 2011
|
35.2 KB |
|
| |
SAN MATEO, Calif., March 28, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today reported financial results for the fourth quarter and full year ended December 31, 2010, and provided a corporate update.
"2010 was a year of significant accomplishments for Talon clinically and financially," stated Steven R. Deitcher, M.D., Pr...
|
|
Talon Therapeutics to Host a Conference Call to Report Fourth Quarter and Full Year 2010 Results and Business Update on March 28, 2011
Mar 24, 2011
|
22.1 KB |
|
| |
SAN MATEO, Calif., March 24, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Monday, March 28, 2011 at 8am PT, to include a discussion of results and highlights of the fourth quarter and full year 2010 and a business update.
Conference call details:
Date:
...
|
|
Talon Therapeutics to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
Mar 14, 2011
|
24.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 14, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics (OTCBB:TLON), announced that Steven R. Deitcher, M.D., President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline programs on Tuesday, March 15, 2011, at 5:00 PM Pacific Time at the Roth Capital Partners 23rd Annual OC ...
|
|
New Patent Issued for Talon Therapeutics' Marqibo(R) Expands Disease Coverage to Include Lymphoma, Leukemia and Myeloma
Mar 10, 2011
|
25.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 10, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON), today announced the issuance of U.S. patent 7,887,836 B2, which covers compositions and methods for treating lymphoma, leukemia and myeloma for Marqibo (vincristine sulfate liposome injection). The patent expires in March 2020. A previously issued...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
RSS News Feeds